Evidence Table E59. Binge eating disorder drug treatment – part 5

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Arnold, 200266 | Binges/wk  | Binges/wk:G1: 6.0 (2.5)G2: 6.1 (4.8)(P = NS) | Binges/wkEndpoint:G1: 1.8 (2.9)G2: 2.7 (3.8)Diff between groups (P = NR) Diff between groups in change over time (time trend analysis, P = 0.033; endpoint analysis, P = NS)Response Categories (% decrease in binges/wk from baseline to endpoint)Intent to treat sample: G1 = 29; G2 = 21None (<50%): G1: 7 (24); G2: 9 (43) Moderate (50%-74% decrease): G1: 8 (28); G2: 4 (19)Marked (75%-99% decrease): G1: 1 (3); G2: 3 (14) Remission (100%): G1: 13 (45) (P = NR) G2: 5 (24) (P = NR)Diff between groups (P = NS) Diff between groups in change over time (P = NR) |
| Brownley, 201367 | Binges per 28 days | Binges per 28 daysbaselineG1: 31.0 (24.8)G2: 12.8 (3.6)G3: 16.7 (9.5)p = 0.39 | Binges per 28 daysMonthly rate of changeG1: -1.65 (0.76)G2: -0.93 (0.70)G3: -0.97 (0.78)p = NS |

Evidence Table E59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200968 | Binges/wkBinge days/wk | Binges/wk (M,SD)G1: 3.92 (1.47)G2: 3.28 (1.31)Binge days/wk (M,SD) G1: 3.81 (1.39)G2: 3.20 (1.26) | Binges/wk (M,SD)G1: 1.65 (2.35)G2: 0.76 (1.71)Diff between groups (p = 0.151) Diff between groups in change over time (p =0.958)Binge days/wk (M, SD)G1: 1.58 (2.212)G2: 0.76 (1.71)Diff between groups (p = 0.156) Diff between groups in change over time (p =0.900)Response Categories (% decrease in binges/wk from baseline to endpoint)Intent to treat sample: G1 = 25; G2 = 24None (<50%): G1: 5 (20); G2: 3 (13) Moderate (50%-74% decrease): G1: 4 (16); G2: 2 (8)Marked (75%-99% decrease): G1: 3 (12); G2: 1 (4) Remission (100%): G1: 13 (52); G2: 18 (75) (P = NS)Diff between groups (P = NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200869 | Binge episodes/weekBinge days/weekResponse categories for % decrease in frequency of binges from BL to endpoint-none (<50%)-moderate (50-74%)-marked (75-99%)-remission (100%) | Binge episodes/week, M (SD)G1: 4.9 (2.6)G2: 5.1 (2.3)p=NSBinge days/week, M (SD)G1: 4.0 (1.7)G2: 4.1 (1.5)p=NS | Binge episodes/week, M (SD)G1: 0.9 (1.4) G2: 1.7 (1.5)Time-trend analysisEstimate between-group difference in 12-week change (95% CI): -0.27 (-0.50, 0.07)chi-square: 2.7p=0.100Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): -0.31 (-0.52, 0.03)t=2.17p=0.036Binge days/week, M (SD)G1: 0.9 (1.4)G2:1.6 (1.4)Time-trend analysisEstimate between-group difference in 12-week change (95% CI): -0.28 (-0.50, 0.05)chi-square: 2.95p=0.102Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): -0.31 (-0.52, 0.01)t=2.10p=0.042ITT analysis Response: NoneG1: 3 (15%)G2: 5 (22%)ModerateG1: 3 (15%)G2: 9 (39%) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200869(continued) |  |  | MarkedG1: 4 (20%)G2: 3 (13%)RemissionG1: 10 (50%)G2: 6 (26%)p=0.088 for difference between groupsCompleter analysis Response: NoneG1: 2 (12%)G2: 3 (16%)ModerateG1: 2 (12%)G2: 8 (42%)MarkedG1: 5 (29%)G2: 2 (11%)RemissionG1: 8 (47%)G2: 6 (32%)p=0.176 for difference between groups |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 201270 | Binge day frequency - the number of days per week that a participant engaged in at least one binge episodeBinge episode frequency per week | Binge days/wk, M (SD)G1: 4.0 (1.8)G2: 3.5 (1.5)p = NRBinges/wk, M (SD)G1: 4.5 (2.0)G2: 4.0 (2.4)p = NR | Binge days/wk, M (SD)G1: 1.0 (1.7)G2: 1.3 (1.2)Longitudinal analysis d = 0.67p = 0.04Endpoint analysisd = 0.47p = 0.15Binges/wk, M (SD)G1: 1.1 (2.0)G2: 1.3 (1.2)Longitudinal analysis d = 0.78p = 0.02Endpoint analysisd = 0.36p = 0.27Response: NoneG1: 3 (17%)G2: 3 (30%)ModerateG1: 1 (6%)G2: 4 (20%)MarkedG1: 4 (22%)G2: 4 (20%)RemissionG1: 10 (56%)G2: 6 (30%)p=0.09 for difference between groups |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Hudson, 199871 | Binge frequency: Number of binges experienced since the last visit (visits were weekly)Additional analyses examined categorical variable of % decrease in frequency of binges from BL to 9wk | Binges/wk, M (SD)G1: 5.4 (2.9)G2: 5.3 (2.5)p=NR, NS | Binges/wk (intent-to-treat), in mean log ([binges/week]+1):G1: depicted in graphG2: depicted in graphTreatment-by-time interaction:-0.181 (SE 0.066)p=0.006G1 > G2Response categoriesITT AnalysisRemission (100% decrease)G1: 15 (38%)G2: 11 (26%)Marked response (75%-99% decrease)G1: 3 (8%)G2: 3 (7%)Moderate response (50%-74% decrease)G1: 7 (18%)G2: 7 (16%)No response (<50%)G1: 15 (38%)G2: 22 (51%)Fisher's exact test, p = NRCompleter AnalysisRemissionG1: 13 (45%)G2: 9 (24%)Marked responseG1: 2 (7%)G2: 3 (8%)Moderate responseG1: 6 (21%)G2: 6 (16%)No responseG1: 8 (28%)G2: 20 (53%)Fisher's exact test, p = 0.04 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Hudson, 199871(continued) |  |  | Evaluable-subjects--those who completed 4wks): RemissionG1: 15 (44%)G2: 10 (24%)Marked responseG1: 3 (9%)G2: 3 (7%)Moderate responseG1: 6 (18%)G2: 7 (17%)No responseG1: 10 (29%)G2: 21 (51%)Fisher's exact test, p = 0.04 |
| Leombruni, 200872 | Binges/weekAbstinence | Binges/wkG1: 4.6 (3.2)G2: 6.2 (7.3) | Binges/wkT8G1: 1.3 (1.9)G2: 0.8 (1.1)T12G1: 1.3 (2.0)G2: 0.6 (0.6)T24G1: 0.9 (1.1)G2: 1.1 (3.3)Time effect p = 0.000Time x group p = 0.467 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200773 | Binges/wk: binge frequency - mean # of binges per week in the interval between visitsBinge days/wk: weekly frequency of binge days - days when the pt. had 1 or more binges | Binges/wk: G1: 4.2 (1.4)G2: 4.9 (2.5)Binge days/wk:G1: 3.8 (1.1)G2: 3.9 (1.5) | Binges/wk: Longitudinal AnalysisEstimate (mean change btwn g1-g2): -0.4195% CI: -0.61 to -0.09X^2: 5.27p: 0.81Endpoint AnalysisEstimate (mean change btwn g1-g2):-0.1695% CI: -0.29 to - 0.01t: 2.20p: 0.34Binge days/wk:Longitudinal AnalysisEstimate (mean change btwn g1 - g2): -0.4595% CI: -0.63 to - 0.18X^2: 8.75p: 0.003Endpoint AnalysisEstimate (mean change btwn g1 - g2): -0.1695% CI: -0.30 to - 0.03t: 2.37p: 0.023 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200674 | Binge frequency (mean number of binges per week)Binge days/weekBinge response to treatment categories-remission: cessation of binges-marked: 75%-99% decrease-moderate: 50-74% decrease-none: <50% decreaseTime to recovery (recovery = first 4 conse | Binges/wk, mean (SD):G1: 4.7 (SD 1.4)G2: 4.4 (SD 2.0)Binge days/wk, mean (SD):G1: 3.9 (SD 1.1)G2: 3.9 (SD 1.3) | Binges/wkLongitudinal analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.315 (95% CI -0.504 to -0.055); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scalep=0.021Endpoint analysis G1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): 0.002 (95% CI -0.143 to 0.171); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scalep=0.979Binge days/wkLongitudinal analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.271 (95% CI -0.476 to 0.016); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scale |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200674(continued) |  |  | p=0.082Endpoint analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -0.040 (95% CI -0.176 to 0.119); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scalep=0.596Categorical response: ITT analysisNoneG1: 5 (18%)G2: 4 (14%)ModerateG1: 4 (14%)G2: 7 (24%)MarkedG1: 4 (14%)G2: 5 (17%)RemissionG1: 15 (54%)G2: 13 (45%)p=0.82 (NS difference between groups) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200375 | Binge frequency: Number of binges experienced since the last visit (visits were weekly), per clinical interview and review of take-home diariesWeekly frequency of binge days (days during which there were 1 or more binges)Additional analyses examined c | Binges/wk, mean (SD)G1: 5.2 (3.6)G2: 5.7 (2.6)p=NR, NSBinge days/wkG1: 4.0 (1.7)G2: 4.0 (1.5)p=NR, NS | Binges/wk, mean (SD)G1: 1.7 (3.1)G2: 3.4 (3.0)Time Trend Analysis: Diff b/t groups in rate of change, standardized at 5.5 binges/wk:-1.7p = 0.003Endpoint Analysis: Diff b/t groups in change from BL to 6wk, standardized at 5.5 binges/wk:-1.1p = 0.091Binge days/wk, mean (SD)G1: 1.2 (2.0)G2: 2.8 (2.2)Time Trend Analysis: Diff b/t groups in rate of change, standardized at 4.0 binge days/wk:-1.6p < 0.001Endpoint Analysis: Differences between groups in change from BL to 6wk, standardized at 4.0 binge days/wk:-1.2p = 0.016Response categoriesITT Analysis:None (<50%)G1: 5 (26)G2: 11 (58)Moderate (50-74%)G1: 4 (21)G2: 3 (16)Marked (75-99%)G1: 1 (5)G2: 1 (5) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200375(continued) |  |  | Remission (100%)G1: 9 (47)G2: 4 (21)p=0.068 for difference between groups, by exact trend test |
| McElroy, 200376 | Binges/wkBinge days/wkCategorical response:None (< 50% reduction)Moderate (50% to 74% reduction)Marked (75% to 99% reduction)Remission (100% reduction - zero binges) | Binges/wk, mean (SD):G1: 5.3 (2.8)G2: 6.3 (2.8)Binge days/wk, mean (SD):G1: 4.3 (1.8)G2: 4.8 (1.8) | Binges/wk (% decrease)G1: 94%G2: 46%Diff between groups, p = NSDiff between groups in change over time, p = 0.02Diff between groups in rate of change, p = 0.0004Binge Days/wk (% decrease)G1: 93%G2: 46%Diff between groups, p = NSDiff between groups in change over time, p = 0.02Diff between groups in rate of change, p = 0.0001Categorical Response, %:None:G1: 18%G2: 37%Moderate:G1: 7%G2: 23%Marked:G1: 11%G2: 10%Remission:G1: 64%G2: 30% |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200077 | Binges per week | Binges/wk, mean (SD):G1: 7.6 (4.8)G2: 7.2 (5.8)p = 0.83G1: LOG: 2.04 (0.48)G2: LOG: 1.97 (0.52) p = 0.69 | Binges/wk:Difference in change between G1 and G2, mean, expressed as log([binges/wk]+1): -0.441SE:0.163p = 0.008G1 better than G2Among completers:Binges/wkG1: 1.13 (1.56)G2: 3.85 (3.81)Categorical response. N:None (< 50% reduction)G1: 0G2: 3Moderate (50% to 74% reduction)G1: 3G2: 4Marked (75% to 99% reduction)G1: 2 G2: 3Remission (100 % reduction)G1: 7G2: 2 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201178 | Binge episode frequency per weekBinge day frequency - the number of days per week that a participant engaged in at least one binge episodeCategorical response:None (< 50% reduction)Moderate (50% to 74% reduction)Marked (75% to 99% reduction)Remiss | Binges episodes/wk, mean (SD)G1: 4.5 (2.1)G2: 4.5 (2.2)p = NR, NSBingedays/wk, mean (SD)G1: 4.2 (1.7)G2: 3.8 (1.2)p = NR, NS | Binges episodes/wk, mean (SD)G1: 1.9 (2.4)G2: 2.8 (2.5)p = 0.61Binge days/wk, mean (SD)G1: 1.8 (2.2)G2: 2.6 (2.1)p = 0.23 Categorical Response:None: G1: 32%G2: 50%Moderate: G1: 21%G2: 20%Marked: G1: 16%G2: 10%Remission: G1: 32%G2: 20% p = NR, stated as NS |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200779 | Binge episode frequency per weekBinge day frequency - the number of days per week that a participant engaged in at least one binge episodeCategorical response, binge days:None (< 50% reduction)Moderate (50% to 74% reduction)Marked (75% to 99% reduc | Binges episodes/wk, mean (SD)G1: 6.6 (4.6)G2: 6.3 (3.6)p = NRBingedays/wk, mean (SD)G1: 4.6 (1.3)G2: 4.6 (1.3)p = NR | Binge episodes/wk, mean (SD) change from baselineG1: -3.5 (1.9)G2: -2.5 (2.1)Endpoint Analysis: p < 0.001Longitudinal Analysis, rate of change: p < 0.001Binge days/wk, mean (SD) change from baselineG1: -5.0 (4.3)G2: -3.4 (3.8)Endpoint Analysis: p < 0.001Longitudinal Analysis, rate of change: p < 0.001Categorical response, binge days:NoneG1: 20%G2: 42%ModerateG1: 10%G2: 18%MarkedG1: 12%G2: 11%RemissionG1: 58%G2: 29%p < 0.001 for group difference across categories |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201380 | Binge days/wkBinge days responder categories -≥1 less day-≥2 less day-≥3 less dayWeekly binge frequencyWeekly binge frequency responder categories -≥2 binges-≥3 binges-≥4 bingesRemission: no binges in the last 2 study weeks or in interval be | Binge days/wk, mean (SD)G1: 3.4 (1.0)G2: 3.7 (1.5)p=0.35Binges/wk, mean (SD)G1: 4.4 (2.3)G2: 4.3 (2.3)p=0.87 | Endpoint means NRWeekly binge days, mean change (SD) from baseline to endpoint:G1: -2.4 (1.6)G2: -2.7 (.5)p=0.50Binge days responder-≥1 day, N (%) from baseline to endpoint, N (%):G1: 20 (77%)G2: 32 (89%)p=0.30Binge days responder-≥2 day, N (%) from baseline to endpoint:G1: 18 (69%)G2: 24 (67%)p=0.83Binge days responder-≥3 day, N (%) from baseline to endpoint:G1: 11 (42%)G2: 18 (50%)p=0.55Weekly binge frequency, mean change (SD) from baseline to endpoint:G1: -3.3 (2.4)G2: -3.2 (1.8)p=0.99Binge frequency responder-≥2 binges, N (%) from baseline to endpoint:G1: 19 (73%)G2: 26 (SD 72%)p=0.94Binge frequency responder-≥3 binges, N (%) from baseline to endpoint:G1: 16 (SD 62%)G2: 20 (SD 56%)p=0.64 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201380(continued) |  |  | Binge frequency responder-≥4 binges, N (%) from baseline to endpoint:G1: 10 (38%)G2: 13 (SD 36%)p=0.85Remission, N (%)G1: 9 (35%)G2: 19 (53%)p=0.16 |
| McElroy, 201581 | Binge days per week | Binge days/week, nontransformed mean (SD)G1: 4.5 (SD 1.44)G2: 4.5 (SD 1.28)G3: 4.6 (SD 1.25)G4: 4.3 (SD 1.38)Binge episodes, non-transformed, mean (SD)G1: 5.8 (SD 3.03)G2: 5.6 (SD 2.75)G3: 5.6 (SD 2.43)G4: 5.2 (SD 2.13) | Primary efficacy variables11wk Binge days/week, nontransformed mean (SD)G1: 1.0 (SD 1.69)G2: 0.4 (SD 0.86)G3: 0.5 (SD 1.25)G4: 1.1 (SD 1.45)11wk change from BL, Binge days/week, log-transformed, LS, mean (SE)G1: -1.24 (SE 0.067)G2: -1.49 (SE 0.066)G3: -1.57 (SE 0.067)G4: -1.23 (SE 0.069)11wk difference from placebo, Binge days/week, nontransformed mean (SD)G1: -0.01 (SE 0.096)G2: -0.26 (SE 0.096)G3: -0.35 (SE 0.096)G4: N/ABinge days/week Significant difference compared with placeboG1 p=0.88G2 p=0.008G3 p<0.001G4 N/A |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201581(continued) |  |  | Secondary efficacy variables11wk binge episodes, non-transformed, mean (SD)G1: 1.2 (SD 2.13)G2: 0.5 (SD 1.01)G3: 0.5 (SD 1.34)G4: 1.1 (SD 1.55)11wk change from BL, Binge episodes, log-transformed, LS, mean (SE)G1: -1.37 (SE 0.070)G2: -1.62 (SE 0.069)G3: -1.71 (SE 0.070)G4: -1.36 (SE 0.072)11wk difference from placebo, Binge episodes, nontransformed mean (SD)G1: -0.01 (SE 0.100)G2: -0.27 (SE 0.100)G3: -0.35 (SE 0.100)G4: N/ABinge episodes Significant difference compared with placeboG1 p=0.89G2 p=0.009G3 p<0.001G4 N/A1wk Cessation (100% reduction) Binge response category (%)G1: 42.4%G2: 51.6%G3: 55.6%G4: 37.1%1wk Marked response (75-<100% reduction) Binge response category (%)G1: 30.3%G2: 37.5%G3: 36.5%G4: 24.2% |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201581(continued) |  |  | 1wk Moderate response (50-<75 reduction) Binge response category (%)G1: 12.1%G2: 6.3%G3: 1.6%G4: 21.0%1wk Negative/minimal response (<25% reduction) Binge response category (%)G1: 15.2%G2: 4.7%G3: 6.3%G4: 17.7%1wk Binge category response: Significant difference compared with placeboG1 p=0.33G2 p=0.006G3 p=0.002G4 N/A4wk Cessation (100% reduction) Binge response category (%)G1: 34.9%G2: 42.2%G3: 50.0%G4: 21.3%4wk Binge cessation: Significant difference compared with placeboG1 p=0.09G2 p=0.01G3 p<0.001G4 N/A |
| Pearlstein, 200382 | Number of binge days, past 28 days | Days Binged (M,SD)G1: 14.67 (55.68)G2: 20.00 (6.21)(P = NS) | Days Binged (M,SD)G1: 3.11 (4.20) G2: 7.31 (9.31)Diff between groups (P = NR)Change over time for both groups: (P < 0.001)Diff between groups in change over time (P=NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Shire, 201483,84 | Number of binge days per week4-week abstinence | Number of binge days per weekG1: 4.66 (1.27)G2: 4.82 (1.42) | Change in number of binge days per week measured as LS mean (SEM)G1: -3.92 (0.135) SD: 0.14G2: -2.26 (0.137) SD: 0.14LS Mean diff (95% CI): -1.66 (-2.04 to -1.28)(p< 0.001)4-week abstinenceG1: 36.2% (29.1-43.3)G2: 13.1% (8.1-18.0)Diff: 25.9% (p < 0.001)Change in number of binge episodes per weekG1: -5.54 (0.193)G2: -3.31 (0.194)Diff: -2.23 (-2.77 to -1.69) (p < 0.001) |
| Shire, 201484,85 | Number of binge days, past 28 days | Days Binged (M,SD)G1: 14.67 (55.68)G2: 20.00 (6.21)(P = NS) | Days Binged (M,SD)G1: 3.11 (4.20) G2: 7.31 (9.31)Diff between groups (P = NR)Change over time for both groups: (P < 0.001)Diff between groups in change over time (P=NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| White, 201386 | Objective binge eating (OBE) episodes, EDE monthlyObjective binge eating (OBE) episodes, self-report weekly (via daily monitoring)Subjective binge eating (SBE) episodes, EDE monthlySubjective binge eating (SBE) episodes, self-report weekly (via dail | OBE episodes, EDE monthly G1: 17.8 (SD 11.9)G2: 13.6 (SD 6.5)OBE episodes, SR weeklyG1: 3.3 (SD 3.3)G2: 3.0 (SD 2.6)SBE episodes, EDE monthlyG1: 13.5 (SD 11.2)G2: 10.3 (SD 14.2)SBE episodes, SR weeklyG1: 3.6 (SD 2.7)G2: 2.7 (SD 3.4) | 8wk OBE episodes, EDE monthly G1: 5.0 (SD 9.4)G2: 6.3 (SD 8.0)Mixed effects model medication effectF=0.08, p=0.788wk OBE episodes, SR weeklyG1: 0.8 (SD 1.2)G2: 1.0 (SD 1.5)Mixed effects model medication effectF=2.01, p=0.168wk SBE episodes, EDE monthlyG1: 9.3 (SD 21.4)G2: 7.5 (SD 8.4)Mixed effects model medication effectF=0.96, p=0.338wk SBE episodes, SR weeklyG1: 2.2 (SD 4.2)G2: 2.3 (SD 2.4)Mixed effects model medication effectF=0.47, p=0.508wk Categorical remission from binge episodes (no binge episodes during the past 4 weeks)G1: 42%G2: 27%Chi-square=1.58, phi coefficient=0.16, p=0.21 |